What results were seen from the AURORA Study?
The AURORA Study, an international double-blind randomized trial, assigned 2776 HD patients to receive rosuvastatin 10 mg daily or placebo, and followed for a median of 3.8 years. Despite the mean reduction in LDL-C of 43% in the intervention group, the combined primary endpoint of death from cardiovascular causes, nonfatal MI, or nonfatal stroke was not reduced (HR 0.96; 95% CI 0.84 1.11; p 0.59). Rosuvastatin did not reduce the risk of individual components of the primary endpoint, nor of all-cause mortality (HR 0.96; 95% CI 0.86- 1.07; p 0.51).